the AGM presentation has a paragraph under regulatory approval " planning for single phase 11 to single phase 3 -possible with strong efficacy data"
Does that mean that Phase 2 data should be enough to get approval. i was under the impression that Phase 3 would be a short simple trial, because of the amount of data and studies already done. the Phase 2 was everything as far as investors are concerned in this case.
it appears that the bar for approval is set very low. just stopping convulsions is enought for approval.
They already know that it stops convulsions and have toxicity studies from 1700 people without any concern.
This is looking like we have overcome nearly Ll hurdles and risks. the money to get there is in the bank.
So whoever has been accumulating has done their homework on this one
Did anybody make the AGM.
PoS
the AGM presentation has a paragraph under regulatory approval "...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.52 |
Change
0.660(3.32%) |
Mkt cap ! $2.622B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $6.431M | 315.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1024 | $20.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.53 | 285 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |